SEC For	m 4																		
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549														OMB APPROVAL				
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					pursuan	t to Sectio tion 30(h)	n 16(	(a) of	f the Seci	uritie	es Exchan	_	HIP	Estim	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
1. Name and Address of Reporting Person <sup>*</sup> Chardonnet Laurent					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Prelude Therapeutics Inc</u> [ PRLD ]									(Che	ck all applica Director	able)	,		er mer pecify
(Last) (First) (Middle) C/O PRELUDE THERAPEUTICS INCORPORATED 200 POWDER MILL ROAD					3. Date of Earliest Transaction (Month/Day/Year) 11/29/2021										X Officer (give title Other (sj below) below) Chief Financial Officer				peeny
(Street) WILMINGTON DE 19801					4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing Line) X Form filed by One Report Form filed by More than Person											e Repo	rting Person		
(City) (State) (Zip)																			
		Та	ble I - Non-	Deriva	tive S	ecuritie	s Ac	cqui	iired, D	isp	osed o	of, or	Ben	eficially	Owned				
Date				2. Transac Date (Month/Da	Execution Dat			Code (Inst				ities Acquired (A) d d Of (D) (Instr. 3, 4			5. Amoun Securities Beneficia Owned Fo Reported	s Ily	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code V	/	Amount		A) or D)	Price	Transaction(s) (Instr. 3 and 4)				instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Cod	isaction e (Instr.	5. Numb Derivativ Securitie Acquired or Dispo of (D) (In 3, 4 and	ve es d (A) sed str.	Exp	6. Date Exercisable Expiration Date (Month/Day/Year)			nd 7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		s Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	e V	(A)	(D)	Dat Exe	ite ercisable		piration ate	Title		Amount or Number of Shares		(Instr. 4)			
Employee Stock Option (Right to Buy)	\$13.75	11/29/2021		A		180,000			(1)	11	/28/2031	Comm Stoc		180,000	\$0.00	180,0	00	D	

Explanation of Responses:

1. The stock option vests as to 25% of the total shares on November 29, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

## <u>/s/ Krishna Vaddi, Attorney-in-</u> <u>Fact</u>

12/01/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.